Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

Summary

The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.

Timeline

Start

2010-07

Primary completion

2012-02

Completion

2012-02

Publications

• Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, Martin L, Thebault C, Ruban C, Benhamou PH. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016 Apr;137(4):1258-1261.e10. doi: 10.1016/j.jaci.2016.01.008. Epub 2016 Feb 24. No abstract available.

Drugs

Indications